書籍詳細

■ 統計

P.17 掲載の参考文献

• 1) Takahashi K, Saito K, Tanabe K et al.:Multicenter cooperative study group. First report of a seven-year survey on ABO-incompatible kidney transplantation in Japan. Clin Exp Nephrol 5:119-125, 2001.

• 2) Takahashi K, Saito K, Takahara S et al:Excellent longterm outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 4:1089-1096, 2004.

• 3) Takahashi K, Saito K:The Japanese ABO-incompatible Kidney Transplantation Committee:Present status of ABO-incompatible kidney transplantation in Japan. Xenotransplant 13 :118-122, 2006.

• 4) Takahashi K:ABO-incompatible organ transplantation. Curr Opin Organ Transplant 12:409-414, 2007.

• 5) Takahashi K:Chapter 6. Accommodation in ABO-incompatible kidney transplantation-Why do kidney grafts survive? Accommodation in ABO-incompatible Kidney Transplantation. Elsevier, Amsterdam, 2004, p37-52.

• 6) Takahashi K:A new concept of accommodation in ABO-incompatible kidney transplantation. Clin Transplant 19(supple 14):76-85, 2005.

• 7) Takahashi K:A new immunosuppressive therapy in ABO-incompatible kidney transplantation besed on a new concept of accommodation. ABO-incompatible Organ Transplantation From JAPAN. (ed Takahahi K), Elsevier, Amsterdam, 2006, p73-87.

• 8) Ogawa H, Mohiuddin MM, Galili U et al.:Mouse-heart grafts expressing an incompatible carbohydrate antigen. II Transition from accommodation to tolerance. Transplantation 77:366-373, 2004.
  pubmed

• 9) Galili U:Xenotransplantation and ABO-incompatible transplantation;the similarities they share. Transfus Apher Sci 35:45-58, 2006.
  pubmed

• 10) West LJ:B-cell tolerance following ABO-incompatible infant heart transplantation. Transplantation 81:301-307, 2006.
  pubmed

• 11) Takahashi K:Chapter 8:Timing of the start of immunosuppressive therapy (duration of desensitization therapy). Accommodation in ABO-incompatible Kidney Transplantation. Elsevier, Amsterdam, 2004, p94-95.

• 12) Takahashi K:ABO-incompatible kidney transplantation-Establishing a scientific framework. Elsevier, Amsterdam, 2007, p38-52.

• 13) Saito K, Nakagawa Y, Takahashi K et al.:Pinpoint targeted immunosuppression;Anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. Xenotransplant 13:111-117, 2006.

• 14) Takahashi K:Recent findings of ABO-incompatible kidney transplantation-Classification and therapeutic strategy for acute antibody-mediated rejection due to ABO-bloog group-related antigens during critical period preceding establishment of accommodation. Clin Exp Nephrol 11:128-141, 2007.

• 15) Tyden G, Kumlien G, Genberg H et al.:ABO-incompatable kidney transplantation without splenectomy using antigen-specific immunoadsorption and rituximab. Am J Transplant 5:145-148, 2005.

• 16) Kobayashi T, Saito K:A series of surveys on assay for anti-A/B antibody by Japanese ABO-incompatible Transplantation Committee. Xenotransplantation 13(2):136-140, 2006.

• 17) Alexandre GPJ, Squifflet JP, Bruyere MDE et al.:Splenectomy as a prerequisite for human ABO-incompatible renal transplantation. Transplant Proc 17:138-143, 1985.

• 18) Irei T, Ohdan H, Zhou W et al:The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1cell differentiation blockade:novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation. Blood 110:4567-4575, 2007.

• 19) Tasaki M, Yoshida Y, Miyamoto M et al.:Identification and characterization of major proteins carrying ABO blood group antigens in the human kidney. Transplantation 87(8):1125-1133, 2009.
  pubmed

• 20) Iwasaki K, Miwa Y, Ogawa H et al.:Comparative study on signal transduction in endothelial cells after anti-A/B and human leukocyte antigen antibody reaction:implication of accommodation. Transplantation 93(4):390-397, 2012.

• 21) Takahashi K, Saito K, Nakagawa Y, Tasaki M, Imai N, Hara N:Mechanism of acute antibody-mediated rejection in ABO-incompatible kidney transplantation:which anti-A/anti-B antibodies are responsible, natural or de novo? Transplantation 89(5):635-637, 2010.
  pubmed

• 22) Takahashi K, Saito K:ABO-incompatible kidney transplantation. Transplantation Reviews 27(1):1-8, 2013.
  pubmed

P.36 掲載の参考文献

• 1) Lindberg L, Johansson SM, Liu J, Grufman P, Holgersson J:Is there a clinical need for a diagnostic test allowing detection of chain type-specific anti-A and anti-B? Transfusion 51:494-503, 2011.

• 2) Stussi G, Huggel K, Lutz H, Schanz U, Rieben R, Seebach JD:Isotype-specific detection of ABO blood group antibodies using a novel flow cytometric method. Br J Haematol 130:954-963, 2005.
  pubmed

• 3) Lemy A, Andrien M, Lionet A, Labalette M, Noel C et al.: Posttransplant major histocompatibility complex class I chain-related gene A antibodies and long-term graft outcomes in a multicenter cohort of 779 kidney transplant recipients. Transplantation 93:1258-1264, 2012.

• 4) Reinsmoen N, Lai CH, Heidecke H, Haas M, Cao K et al.: Anti-angiotensin type I receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 90:1473-1477, 2010.
  pubmed

• 5) Nakagawa Y, Saito K, Morioka T, Tomita Y, Takahashi K et al.:The clinical significance of antibody to vascular endothelial cells after renal transplantation. Clin Transplant 16:51-57, 2002.
  pubmed

• 6) Jackson AM, Lucas DP, Melancon JK, Desai NJ:Clinical relevance and IgG subclass determination of non-HLA antibodies identified using endothelial cell precursors isolated from donor blood. Transplantation 92:54-60, 2011.

• 7) Ogasawara K, Ueki J, Takenaka M, Furihata K:Study on the Expression of ABH antigen on platelets. Blood 82:993-999, 1993.

• 8) Curtis BR, Edwards JT, Hessner MJ, Klein JP, Aster RH: Blood group A and B antigens are strongly expressed on platelets of some indivisuals. Blood 96:1574-1581, 2000.

• 9) Cooling LLW, Kelly K, Barton J, Hwang D, Koerner TAW et al.:Determinants of ABH expression on human blood platelets. Blood 105:3356-3364, 2005.

• 10) Sant' Anna Gomes BM, Estalote AC, Palatnik M, Pimenta G, Pereira BB et al:Prevalence, serologic and genetic studies of high expressers of the blood group A antigen on platelets. Transfus Med 20:303-314, 2010.

• 11) Tasaki M, Yoshida Y, Miyamoto M, Nameta M, Cuellar LM et al.:Identification and characterization of major proteins carrying ABO blood group antigens in the human kidney. Transplantation 87:1125-1133, 2009.
  pubmed

P.45 掲載の参考文献

• 1) Zhou W, Ohdan H, Tanaka Y, Hara H, Tokita D et al.: NOD/SCID mice engrafted with human peripheral blood lymphocytes can be a model for investigating B cells responding to blood group A carbohydrate determinant. Transpl Immunol 12(1):9-18, 2003.
  pubmed

• 2) Irei T, Ohdan H, Zhou W, Ishiyama K, Tanaka Y et al.:The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade:novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation. Blood 110(13):4567-4575, 2007.

• 3) Ohdan H, Swenson KG, Kruger Gray HS, Yang YG, Xu Yet al:Mac-1-negative B-1b phenotype of natural antibody-producing cells, including those responding to Gal alpha 1,3Gal epitopes in alpha 1,3-galactosyltransferase-deficient mice. J Immunol 165(10):5518-5529, 2000.

• 4) Minguet S, Dopfer EP, Pollmer C, Freudenberg MA, Galanos C et al:Enhanced B-cell activation mediated by TLR4 and BCR crosstalk. Eur J Immunol 38(9):2475-2487, 2008.
  pubmed

• 5) 山下正博, 田澤宏文, 田中友加, 伊禮俊充, 五十嵐友香・他: マウスB細胞in vitro活性化モデルにおける各種免疫抑制剤感受性. 今日の移植 25(3): 236-238, 2012.
  Medical*Online

• 6) Lebranchu Y, Thierry A, Toupance O, Westeel PF, Etienne I et al.:Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation:concept study. Am J Transplant 9:1115-1123, 2009.
  pubmed

• 7) Tedesco Silva H Jr, Cibrik D, Johnston T, Lackova E, Mange K et al.:Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 10(6):1401-1413, 2010.
  pubmed

• 8) Budde K, Becker T, Arns W, Sommerer C, Reinke P et al.: Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants:an open-label, randomised, controlled trial. Lancet 377(9768):837-847, 2011.
  pubmed

• 9) Neubert K, Meister S, Moser K, Weisel F, Maseda D et al.: The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 14(7):748-755, 2008.
  pubmed

P.54 掲載の参考文献

• 1) Zhang X, Reed EF:Effect of antibodies on endothelium. Am J Transplant 9(11):2459-2465, 2009.
  pubmed

• 2) Iwasaki K, Miwa Y, Haneda M, Uchida K, Nakao A, Kobayashi T:Significance of HLA class I antibody-induced antioxidant gene expression for endothelial cell protection against complement attack. Biochem Biophys Res Commun 391(2):1210-1215, 2010.

• 3) Iwasaki K, Miwa Y, Ogawa H, Yazaki S, Iwamoto M et al.:Comparative study on signal transduction in endothelial cells after anti-A/B and human leukocyte antigen antibody reaction:implication of accommodation. Transplantation 93(4):390-397, 2012.

• 4) Ruderman N, Prentki M:AMP kinase and malonyl-CoA: Targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 3(4):340-351, 2004.
  pubmed

• 5) Shackelford DB, Shaw RJ:The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 9(8):563-575, 2009.
  pubmed

• 6) Chen CY, Jang JH, Li MH, Surh YJ:Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. Biochem Biophys Res Commun 331(4):993-1000, 2005.
  pubmed

• 7) Peralta C, Bartrons RA, Serafin A, Blazquez C, Guzman M et al.:Adenosine monophosphate-activated protein kinase mediates the protective effects of ischemic preconditioning on hepatic ischemia-reperfusion injury in the rat. Hepatology 34(6):1164-1173, 2001.

• 8) Bouma HR, Ketelaar ME, Yard BA, Ploeg RJ, Henning RH:AMP-activated protein kinase as a target for preconditioning in transplantation medicine. Transplantation 90(4):353-358, 2010.

• 9) Yamada K, Miwa T, Liu JN, Nangaku M, Song WC:Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol 172(6):3869-3875, 2004.

• 10) Baur JA, Sinclair DA:Therapeutic potential of resveratrol:the in vivo evidence. Nat Rev Drug Discov 5(6):493-506, 2006.
  pubmed

P.61 掲載の参考文献

• 1) Farges O, Kalil AN, Samuel D, Saliba F, Arulnaden JL et al:The use of ABO-incompatible grafts in liver transplantation:a life-saving procedure in highly selected patients. Transplantation 59:1124-1133, 1995.
  pubmed

• 2) Tanabe M, Shimazu M, Wakabayashi G, Hoshino K, Kawachi S et al.:Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation 73:1959-1961, 2002.
  pubmed

• 3) Kozaki K, Egawa H, Kasahara M, Oike F, Yoshizawa A et al.:Therapeutic strategy and the role of apheresis therapy for ABO incompatible living donor liver transplantation. Ther Apher Dial 9:285-291, 2005.
  pubmed

• 4) Yoshizawa A, Sakamoto K, Ogawa M, Kasahara M, Uryuhara K et al.:New protocol of immunosuppression for liver transplantation across ABO-barrier:the use of rituximab, hepatic arterial infusion, and preservation of spleen. Transplant Proc 37:1718-1719, 2005.

• 5) Egawa H, Teramukai S, Haga H, Tanabe M, Fukushima M, Shimazu M:Present status of ABO-incompatible living donor liver transplantation in Japan. Hepatology 47:143-152, 2008.
  pubmed

• 6) Egawa H, Ohmori K, Haga H, Tsuji H, Yurugi K et al.:B-cell surface marker analysis for improvement of rituximab prophylaxis in ABO-incompatible adult living donor liver transplantation. Liver Transpl 13:579-588, 2007.
  pubmed

• 7) Browning JL:B-cells move to centre stage:novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5:564-576, 2006.
  pubmed

• 8) Usui M, Isaji S, Mizuno S, Sakurai H, Uemoto S: Experiences and problems pre-operative anti-CD20 monoclonal antibody infusion therapy with splenectomy and plasma exchange for ABO-incompatible living donor liver transplantation. Clin Transplant 21:24-31, 2007.
  pubmed

• 9) Uchiyama H, Mano Y, Taketomi A, Soejima Y, Yoshizumi T et al.:Kinetics of anti-blood type isoagglutinin titers and B lymphocytes in ABO-incompatible living donor liver transplantation with rituximab and plasma exchange. Transplantation 92:1134-1139, 2012

• 10) Paterno F, Shiller M, Tillery G, O'Leary JG, Susskind B et al:Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant 12:2526-2531, 2012.

P.67 掲載の参考文献

• 1) Ikegami T, Soejima Y, Taketomi A, Yoshizumi T, Maehara Y:Living donor liver transplantation for fulminant hepatic failure from ABO-incompatible donors. Transpl Int 21(3):284-285, 2008.
  pubmed

• 2) Tanabe M, Shimazu M, Wakabayashi G, Hoshino K, Kawachi S et al.:Intra-portal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation 73:1959-1961, 2002.

• 3) Tanabe M, Kawachi S, Obara H, Shinoda M, Hibi T et al.: Current progress in ABO-incompatible liver transplantation. Eur J Clin Invest 40(10):943-949, 2010.
  pubmed

• 4) Raut V, Mori A, Kaido T, Ogura Y, Taku I et al.: Splenectomy does not offer immunological benefits in ABO-incompatible liver transplantation with a preoperative rituximab. Transplantation 93(1):99-105, 2012.

• 5) Ikegami T, Taketomi A, Soejima Y, Yoshizumi T, Uchiyama H et al.:Rituximab, IVIG, and plasma exchange without graft local infusion treatment:a new protocol in ABO incompatible living donor liver transplantation. Transplantation 88(3):303-307, 2009.
  pubmed